TY - JOUR
T1 - Risk factors for progression of coronary artery calcification in patients with chronic kidney disease
T2 - The CRIC study
AU - the CRIC Study Investigators
AU - Bundy, Joshua D.
AU - Chen, Jing
AU - Yang, Wei
AU - Budoff, Matthew
AU - Go, Alan S.
AU - Grunwald, Juan E.
AU - Kallem, Radhakrishna R.
AU - Post, Wendy S.
AU - Reilly, Muredach P.
AU - Ricardo, Ana C.
AU - Rosas, Sylvia E.
AU - Zhang, Xiaoming
AU - He, Jiang
N1 - Funding Information:
Funding for the CRIC Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this study was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003, the Johns Hopkins Institute for Clinical and Translational Research (ICTR) UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439, Michigan Institute for Clinical and Health Research UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, and Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131.
Funding Information:
Funding for the CRIC Study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases ( U01DK060990 , U01DK060984 , U01DK061022 , U01DK061021 , U01DK061028 , U01DK060980 , U01DK060963 , and U01DK060902 ). In addition, this study was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003 , the Johns Hopkins Institute for Clinical and Translational Research (ICTR) UL1 TR-000424 , University of Maryland GCRC M01 RR-16500 , Clinical and Translational Science Collaborative of Cleveland , UL1TR000439 , Michigan Institute for Clinical and Health Research UL1TR000433 , University of Illinois at Chicago CTSA UL1RR029879 , Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036 , and Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131 .
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/4
Y1 - 2018/4
N2 - Background and aims: Coronary artery calcification (CAC) is common among patients with chronic kidney disease (CKD) and predicts the risk for cardiovascular disease (CVD). We examined the associations of novel risk factors with CAC progression among patients with CKD. Methods: Among 1123 CKD patients in the Chronic Renal Insufficiency Cohort (CRIC) Study, CAC was measured in Agatston units at baseline and a follow-up visit using electron beam computed tomography or multidetector computed tomography. Results: Over an average 3.3-year follow-up, 109 (25.1%) participants without CAC at baseline had incident CAC and 124 (18.0%) participants with CAC at baseline had CAC progression, defined as an annual increase of ≥100 Agatston units. After adjustment for established atherosclerotic risk factors, several novel risk factors were associated with changes in CAC over follow-up. Changes in square root transformed CAC score associated with 1 SD greater level of risk factors were −0.20 (95% confidence interval, −0.31 to −0.10; p < 0.001) for estimated glomerular filtration rate, 0.14 (0.02–0.25; p = 0.02) for 24-h urine albumin, 0.25 (0.15–0.34; p < 0.001) for cystatin C, −0.17 (−0.27 to −0.07; p < 0.001) for serum calcium, 0.14 (0.03–0.24; p = 0.009) for serum phosphate, 0.24 (0.14–0.33; p < 0.001) for fibroblast growth factor-23, 0.13 (0.04–0.23; p = 0.007) for total parathyroid hormone, 0.17 (0.07–0.27; p < 0.001) for interleukin-6, and 0.12 (0.02–0.22; p = 0.02) for tumor necrosis factor-α. Conclusions: Reduced kidney function, calcium and phosphate metabolism disorders, and inflammation, independent of established CVD risk factors, may progress CAC among CKD patients.
AB - Background and aims: Coronary artery calcification (CAC) is common among patients with chronic kidney disease (CKD) and predicts the risk for cardiovascular disease (CVD). We examined the associations of novel risk factors with CAC progression among patients with CKD. Methods: Among 1123 CKD patients in the Chronic Renal Insufficiency Cohort (CRIC) Study, CAC was measured in Agatston units at baseline and a follow-up visit using electron beam computed tomography or multidetector computed tomography. Results: Over an average 3.3-year follow-up, 109 (25.1%) participants without CAC at baseline had incident CAC and 124 (18.0%) participants with CAC at baseline had CAC progression, defined as an annual increase of ≥100 Agatston units. After adjustment for established atherosclerotic risk factors, several novel risk factors were associated with changes in CAC over follow-up. Changes in square root transformed CAC score associated with 1 SD greater level of risk factors were −0.20 (95% confidence interval, −0.31 to −0.10; p < 0.001) for estimated glomerular filtration rate, 0.14 (0.02–0.25; p = 0.02) for 24-h urine albumin, 0.25 (0.15–0.34; p < 0.001) for cystatin C, −0.17 (−0.27 to −0.07; p < 0.001) for serum calcium, 0.14 (0.03–0.24; p = 0.009) for serum phosphate, 0.24 (0.14–0.33; p < 0.001) for fibroblast growth factor-23, 0.13 (0.04–0.23; p = 0.007) for total parathyroid hormone, 0.17 (0.07–0.27; p < 0.001) for interleukin-6, and 0.12 (0.02–0.22; p = 0.02) for tumor necrosis factor-α. Conclusions: Reduced kidney function, calcium and phosphate metabolism disorders, and inflammation, independent of established CVD risk factors, may progress CAC among CKD patients.
KW - Chronic kidney disease
KW - Coronary artery disease
KW - Epidemiology
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=85042231574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042231574&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2018.02.009
DO - 10.1016/j.atherosclerosis.2018.02.009
M3 - Article
C2 - 29459266
AN - SCOPUS:85042231574
SN - 0021-9150
VL - 271
SP - 53
EP - 60
JO - Atherosclerosis
JF - Atherosclerosis
ER -